kynurenic acid has been researched along with Nerve Degeneration in 24 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The neuroprotective potential of an antagonist (7-chlorokynurenic acid (7-CIKYNA)) and a low efficacy partial agonist (HA-966) for the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex has been examined using a neuronal cell culture/hypoxia model of neurodegeneration." | 7.68 | The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures. ( Horne, AL; Kemp, JA; McKernan, RM; Priestley, T, 1990) |
| "Kynurenic acid (KYNA) was tested as an antagonist of the neurotoxic and epileptogenic effects of the metabolically related brain constituent quinolinic acid (QUIN)." | 5.27 | Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. ( Foster, AC; French, ED; Schwarcz, R; Vezzani, A, 1984) |
| "Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, reduces the clinical deterioration in moderate-to-severe Alzheimer disease (AD) for which other treatments are not available." | 3.72 | Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. ( Grundke-Iqbal, I; Haque, N; Iqbal, K; Li, L; Sengupta, A, 2004) |
| "The neuroprotective potential of an antagonist (7-chlorokynurenic acid (7-CIKYNA)) and a low efficacy partial agonist (HA-966) for the glycine modulatory site on the N-methyl-D-aspartate (NMDA) receptor complex has been examined using a neuronal cell culture/hypoxia model of neurodegeneration." | 3.68 | The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures. ( Horne, AL; Kemp, JA; McKernan, RM; Priestley, T, 1990) |
| " As it did not induce any appreciable side-effect at the protective dose applied in a chronic dosing regime in this mouse model, it appears worthy of further thorough investigations with a view to eventual clinical trials." | 1.37 | Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. ( Freund, TF; Fülöp, F; Klivényi, P; Nyiri, G; Szatmári, I; Szonyi, A; Toldi, J; Vécsei, L; Zádori, D, 2011) |
| " Agonists of the glycine recognition site of NMDA receptors (D-serine and D-alanine) did not have any toxic effect in hippocampal cultures, whereas competitive blockade of the glycine site by 7-chlorokynurenic acid was neuroprotective." | 1.33 | Glycine-induced neurotoxicity in organotypic hippocampal slice cultures. ( Barth, A; Barth, L; Newell, DW; Nguyen, LB, 2005) |
| "Kynurenic acid (KYNA) was tested as an antagonist of the neurotoxic and epileptogenic effects of the metabolically related brain constituent quinolinic acid (QUIN)." | 1.27 | Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. ( Foster, AC; French, ED; Schwarcz, R; Vezzani, A, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 11 (45.83) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 2 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amori, L | 1 |
| Wu, HQ | 3 |
| Marinozzi, M | 1 |
| Pellicciari, R | 1 |
| Guidetti, P | 2 |
| Schwarcz, R | 7 |
| Rákóczi, K | 1 |
| Klivényi, P | 2 |
| Vécsei, L | 2 |
| Zádori, D | 1 |
| Nyiri, G | 1 |
| Szonyi, A | 1 |
| Szatmári, I | 1 |
| Fülöp, F | 1 |
| Toldi, J | 1 |
| Freund, TF | 1 |
| Campesan, S | 1 |
| Green, EW | 1 |
| Breda, C | 1 |
| Sathyasaikumar, KV | 1 |
| Muchowski, PJ | 1 |
| Kyriacou, CP | 1 |
| Giorgini, F | 1 |
| Li, L | 1 |
| Sengupta, A | 1 |
| Haque, N | 1 |
| Grundke-Iqbal, I | 1 |
| Iqbal, K | 1 |
| Barth, A | 1 |
| Nguyen, LB | 1 |
| Barth, L | 1 |
| Newell, DW | 1 |
| Wu, SZ | 1 |
| Jiang, S | 1 |
| Sims, TJ | 1 |
| Barger, SW | 1 |
| Poeggeler, B | 1 |
| Rassoulpour, A | 1 |
| Roberts, RC | 1 |
| Lee, DY | 1 |
| Lee, KS | 1 |
| Lee, HJ | 1 |
| Noh, YH | 1 |
| Kim, DH | 1 |
| Lee, JY | 1 |
| Cho, SH | 1 |
| Yoon, OJ | 1 |
| Lee, WB | 1 |
| Kim, KY | 1 |
| Chung, YH | 1 |
| Kim, SS | 1 |
| Foster, AC | 3 |
| Vezzani, A | 1 |
| French, ED | 2 |
| Pozzo Miller, LD | 1 |
| Mahanty, NK | 1 |
| Connor, JA | 1 |
| Landis, DM | 1 |
| McMaster, OG | 1 |
| Baran, H | 1 |
| Du, F | 2 |
| Boireau, A | 1 |
| Malgouris, C | 1 |
| Burgevin, MC | 1 |
| Pény, C | 1 |
| Durand, G | 1 |
| Bordier, F | 1 |
| Meunier, M | 1 |
| Miquet, JM | 1 |
| Daniel, M | 1 |
| Chevet, T | 1 |
| Jimonet, P | 1 |
| Mignani, S | 1 |
| Blanchard, JC | 1 |
| Doble, A | 1 |
| Lee, SC | 1 |
| Mosinger, JL | 1 |
| Price, MT | 1 |
| Bai, HY | 1 |
| Xiao, H | 1 |
| Wozniak, DF | 1 |
| Olney, JW | 1 |
| Miyamoto, T | 1 |
| Sakurai, T | 1 |
| Okada, Y | 1 |
| McNamara, D | 1 |
| Dingledine, R | 1 |
| Priestley, T | 2 |
| Horne, AL | 1 |
| McKernan, RM | 1 |
| Kemp, JA | 2 |
| Lekieffre, D | 1 |
| Plotkine, M | 1 |
| Allix, M | 1 |
| Boulu, RG | 1 |
| Donald, AE | 1 |
| Willis, CL | 1 |
| Tridgett, R | 1 |
| Calabresi, P | 1 |
| De Murtas, M | 1 |
| Mercuri, NB | 1 |
| Bernardi, G | 1 |
| Shalaby, I | 1 |
| Chenard, B | 1 |
| Prochniak, M | 1 |
3 reviews available for kynurenic acid and Nerve Degeneration
| Article | Year |
|---|---|
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutri | 2009 |
Quinolinic acid and kynurenic acid in the mammalian brain.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; AIDS Dementia Complex; Animals; Aspartic Acid; Biological Tra | 1991 |
The glycine site on the NMDA receptor: pharmacology and involvement in NMDA receptor-mediated neurodegeneration.
Topics: Allosteric Site; Animals; Glycine; Kynurenic Acid; Nerve Degeneration; Receptors, N-Methyl-D-Asparta | 1990 |
21 other studies available for kynurenic acid and Nerve Degeneration
| Article | Year |
|---|---|
Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum.
Topics: Adenosine; Animals; Animals, Newborn; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; D | 2009 |
Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Humans; | 2011 |
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Drosophila melanogaster; Huntington | 2011 |
Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration.
Topics: 2-Amino-5-phosphonovalerate; Alzheimer Disease; Animals; Calcium-Calmodulin-Dependent Protein Kinase | 2004 |
Glycine-induced neurotoxicity in organotypic hippocampal slice cultures.
Topics: Alanine; Animals; Animals, Newborn; Brain Ischemia; Dose-Response Relationship, Drug; Drug Resistanc | 2005 |
Schwann cells exhibit excitotoxicity consistent with release of NMDA receptor agonists.
Topics: 2-Amino-5-phosphonovalerate; Analysis of Variance; Animals; Calcium; Cell Death; Cells, Cultured; Cu | 2005 |
Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity.
Topics: Animals; Astrocytes; Cell Death; Corpus Striatum; Dopamine; Dopamine Agonists; Excitatory Amino Acid | 2007 |
Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Line, | 2008 |
Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid.
Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Hippocampus; Kynurenic Acid; Male; Nerve Dege | 1984 |
Spontaneous pyramidal cell death in organotypic slice cultures from rat hippocampus is prevented by glutamate receptor antagonists.
Topics: 2-Amino-5-phosphonovalerate; Animals; Cell Death; Culture Techniques; Excitatory Amino Acid Antagoni | 1994 |
gamma-Acetylenic GABA produces axon-sparing neurodegeneration after focal injection into the rat hippocampus.
Topics: 2-Amino-5-phosphonovalerate; 4-Aminobutyrate Transaminase; Alkynes; Amino Acids; Aminocaproates; Ani | 1993 |
Neuroprotective effects of RPR 104632, a novel antagonist at the glycine site of the NMDA receptor, in vitro.
Topics: Aminoquinolines; Animals; Benzothiadiazines; Binding, Competitive; Cerebral Cortex; Cyclic GMP; Exci | 1996 |
Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striatum in vivo.
Topics: Animals; Corpus Striatum; Injections, Intraperitoneal; Kynurenic Acid; Kynurenine; Male; Nerve Degen | 2001 |
Blockade of both NMDA and non-NMDA receptors is required for optimal protection against ischemic neuronal degeneration in the in vivo adult mammalian retina.
Topics: Animals; Dose-Response Relationship, Drug; Female; Ischemia; Kynurenic Acid; Light; Nerve Degenerati | 1991 |
Masking effect of NMDA receptor antagonists on the formation of long-term potentiation (LTP) in superior colliculus slices from the guinea pig.
Topics: 2-Amino-5-phosphonovalerate; Animals; Aspartic Acid; Denervation; Dibenzocycloheptenes; Dipeptides; | 1990 |
Dual effect of glycine on NMDA-induced neurotoxicity in rat cortical cultures.
Topics: 2-Amino-5-phosphonovalerate; Animals; Cells, Cultured; Cerebral Cortex; Drug Synergism; gamma-Aminob | 1990 |
The effect of NMDA receptor glycine site antagonists on hypoxia-induced neurodegeneration of rat cortical cell cultures.
Topics: Animals; Binding Sites; Cells, Cultured; Cerebral Cortex; Dizocilpine Maleate; Fetus; Glycine; Hypox | 1990 |
Kynurenic acid antagonizes hippocampal quinolinic acid neurotoxicity: behavioral and histological evaluation.
Topics: Animals; Exploratory Behavior; Hippocampus; Injections, Intraperitoneal; Kynurenic Acid; Male; Micro | 1990 |
Kainic acid on neostriatal neurons intracellularly recorded in vitro: electrophysiological evidence for differential neuronal sensitivity.
Topics: Action Potentials; Animals; Cell Membrane; Corpus Striatum; Dose-Response Relationship, Drug; In Vit | 1990 |
Glycine reverses 7-Cl kynurenate blockade of glutamate neurotoxicity in cell culture.
Topics: Animals; Cells, Cultured; Drug Interactions; Glutamates; Glycine; Hippocampus; Kynurenic Acid; L-Lac | 1989 |
Involvement of excitatory amino acid receptors in the mechanisms underlying excitotoxic phenomena.
Topics: Action Potentials; Amino Acids, Dicarboxylic; Animals; Cell Survival; Dendrites; Epilepsy; Kynurenic | 1986 |